Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript
Janux Therapeutics, Inc. ( JANX ) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy November 9, 2026 8:30 AM EST Company Participants David Campbell - President, Co-Founder, CEO & Direc…
● Business WireNov 9, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from …
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.39 per share a year ago.…
● Business WireNov 5, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quart…
● Business WireNov 2, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biopharmaceutical company developing next-generation immunotherapies, today announced that it will host a virtual event on Monday, Nov…
Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head Survey
Zai Lab (NASDAQ: ZLAB - Get Free Report) and Janux Therapeutics (NASDAQ: JANX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of…
Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)
Janux Therapeutics (NASDAQ: JANX - Get Free Report) and Roivant Sciences (NASDAQ: ROIV - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on t…
● Zacks Investment ResearchSep 15, 2026 · 11:15 ET
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.…
● Business WireSep 14, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1…
Kept in their own lane. A press release is the company talking, not reporting.
Tied to events
No upcoming events in the feeds.
Most covered today
Quiet tape today.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.